Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- UNIVERSITY HEALTH NETWORK
INTRODUCTION: Programmed death-1 (PD-1) axis inhibitors have become standard therapy in advanced non-small-cell lung cancer (NSCLC). Response might be delayed and pseudo-progression occasionally occurs in patients who eventually benefit from treatment. Additional markers beyond programmed death ligand 1 (PD-L1) expression are needed to assist in patient selection, response evaluation, and treatment decisions.
MATERIALS AND METHODS: The relationship between prospectively collected clinical outcomes (response, disease control rate [DCR], treatment duration, overall survival) and hematologic parameters (neutrophil to lymphocyte ratio [NLR], absolute neutrophil count [ANC], and platelet to lymphocyte ratio [PLR]) was explored retrospectively in advanced NSCLC patients treated with PD-1 axis inhibitors at a major cancer center from May 2013 to August 2016. Hematologic parameters at baseline and during treatment (week 2 or 3 and week 8) were included.
RESULTS: Of 88 patients treated with PD-1 axis inhibitors, 22 (25%) experienced partial response. Baseline NLR ≤4 was associated with superior DCR (74% vs. 50%; P = .025), treatment duration (P = .037), time to progression (P = .053), and overall survival (P = .019), with no differential association according to PD-L1 tumor expression. Lower NLR and ANC during treatment were also associated with response to treatment (P = .025 and P = .017, respectively), and treatment duration (P = .036 and P = .008). No association was found between baseline PLR and DCR, response, treatment duration, nor overall survival.
CONCLUSION: Baseline NLR ≤4 and lower NLR and ANC during treatment might correlate with disease control and treatment response and should be explored further as potential predictors of treatment benefit in larger studies.
|Journal||Clinical Lung Cancer|
|Publication status||Published - Sep 2018|
- Adenocarcinoma/drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Biomarkers, Tumor/analysis, Carcinoma, Large Cell/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Squamous Cell/drug therapy, Female, Follow-Up Studies, Humans, Lung Neoplasms/drug therapy, Lymphocytes/pathology, Male, Middle Aged, Neutrophils/pathology, Prognosis, Prospective Studies, Survival Rate